Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

Objective: Intravenous zoledronic acid (ZA) is often replaced with subcutaneous denosumab in patients with bone metastatic cancer. Despite their different pharmacologic mechanisms of action, both denosumab and ZA are effective in bone metastasis but cause osteonecrosis of the jaw (ONJ) as a side eff...

Full description

Bibliographic Details
Main Authors: Higuchi, T. (Author), Kajizono, M. (Author), Kitamura, Y. (Author), Muro, M. (Author), Sasaki, A. (Author), Sendo, T. (Author), Soga, Y. (Author)
Format: Article
Language:English
Published: Mosby Inc. 2018
Subjects:
adult
Adult
aged
Aged
Aged, 80 and over
Bisphosphonate-Associated Osteonecrosis of the Jaw
bisphosphonic acid derivative
bone density conservation agent
Bone Density Conservation Agents
Bone Neoplasms
bone tumor
denosumab
Denosumab
Diphosphonates
female
Female
human
Humans
imidazole derivative
Imidazoles
Japan
jaw osteonecrosis
male
Male
middle aged
Middle Aged
Retrospective Studies
retrospective study
risk factor
Risk Factors
very elderly
zoledronic acid
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items